Mankind Pharma Limited (BOM:543904)
India
· Delayed Price · Currency is INR 2,204.70
-3.65 (-0.17%)
At close: Dec 5, 2025
Mankind Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2019 |
| Revenue | 135,457 | 122,074 | 102,604 | 87,494 | 77,816 | 62,144 | Upgrade
|
| Revenue Growth (YoY) | 22.94% | 18.98% | 17.27% | 12.44% | 25.22% | 5.83% | Upgrade
|
| Cost of Revenue | 40,932 | 36,596 | 33,056 | 30,031 | 24,879 | 18,471 | Upgrade
|
| Gross Profit | 94,525 | 85,479 | 69,549 | 57,463 | 52,937 | 43,673 | Upgrade
|
| Selling, General & Admin | 38,102 | 34,734 | 28,830 | 23,126 | 20,934 | 18,195 | Upgrade
|
| Other Operating Expenses | 23,646 | 20,461 | 15,432 | 15,195 | 12,014 | 8,386 | Upgrade
|
| Operating Expenses | 70,334 | 61,408 | 48,047 | 41,580 | 34,614 | 27,770 | Upgrade
|
| Operating Income | 24,191 | 24,071 | 21,502 | 15,883 | 18,322 | 15,903 | Upgrade
|
| Interest Expense | -7,433 | -4,209 | -278.2 | -402.74 | -557.8 | -193.03 | Upgrade
|
| Interest & Investment Income | 679.1 | 679.1 | 396.1 | 127.67 | 129.25 | 387.27 | Upgrade
|
| Earnings From Equity Investments | 112.5 | 122.4 | 152.1 | 124.24 | 144.48 | 116.77 | Upgrade
|
| Currency Exchange Gain (Loss) | 195.5 | 195.5 | 84.4 | 104.06 | 88.45 | 5.02 | Upgrade
|
| Other Non Operating Income (Expenses) | 747.6 | 1,115 | 878.6 | 536.42 | 486 | 51.17 | Upgrade
|
| EBT Excluding Unusual Items | 18,493 | 21,974 | 22,735 | 16,372 | 18,613 | 16,270 | Upgrade
|
| Impairment of Goodwill | - | - | - | -38.52 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 1,608 | 1,608 | 1,295 | 374.31 | 1,129 | 628.65 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1,614 | 1,614 | 4.8 | 16.65 | -37.41 | -30.45 | Upgrade
|
| Asset Writedown | -50.2 | -50.2 | -91.6 | -97.08 | -57.63 | -38.88 | Upgrade
|
| Other Unusual Items | 8.1 | 8.1 | 24.8 | 41.53 | 85.27 | 77.21 | Upgrade
|
| Pretax Income | 21,683 | 25,163 | 23,979 | 16,712 | 19,746 | 16,916 | Upgrade
|
| Income Tax Expense | 3,966 | 5,097 | 4,572 | 3,616 | 5,216 | 3,986 | Upgrade
|
| Earnings From Continuing Operations | 17,717 | 20,066 | 19,408 | 13,097 | 14,530 | 12,930 | Upgrade
|
| Earnings From Discontinued Operations | 23.1 | 45.3 | 9.8 | - | - | - | Upgrade
|
| Net Income to Company | 17,740 | 20,111 | 19,418 | 13,097 | 14,530 | 12,930 | Upgrade
|
| Minority Interest in Earnings | -231.4 | -201.6 | -288.7 | -278.17 | -194.81 | -276.07 | Upgrade
|
| Net Income | 17,508 | 19,910 | 19,129 | 12,819 | 14,335 | 12,654 | Upgrade
|
| Net Income to Common | 17,508 | 19,910 | 19,129 | 12,819 | 14,335 | 12,654 | Upgrade
|
| Net Income Growth | -17.22% | 4.08% | 49.23% | -10.58% | 13.28% | 22.81% | Upgrade
|
| Shares Outstanding (Basic) | 410 | 404 | 401 | 401 | 401 | 401 | Upgrade
|
| Shares Outstanding (Diluted) | 411 | 405 | 401 | 401 | 401 | 401 | Upgrade
|
| Shares Change (YoY) | 2.34% | 0.88% | 0.14% | 0.00% | - | - | Upgrade
|
| EPS (Basic) | 42.70 | 49.28 | 47.75 | 32.00 | 35.78 | 31.59 | Upgrade
|
| EPS (Diluted) | 42.63 | 49.19 | 47.68 | 32.00 | 35.78 | 31.59 | Upgrade
|
| EPS Growth | -19.12% | 3.16% | 49.02% | -10.57% | 13.27% | 22.82% | Upgrade
|
| Free Cash Flow | 23,527 | 19,526 | 18,371 | 10,243 | 4,549 | 8,318 | Upgrade
|
| Free Cash Flow Per Share | 57.28 | 48.25 | 45.79 | 25.57 | 11.36 | 20.77 | Upgrade
|
| Gross Margin | 69.78% | 70.02% | 67.78% | 65.68% | 68.03% | 70.28% | Upgrade
|
| Operating Margin | 17.86% | 19.72% | 20.96% | 18.15% | 23.55% | 25.59% | Upgrade
|
| Profit Margin | 12.93% | 16.31% | 18.64% | 14.65% | 18.42% | 20.36% | Upgrade
|
| Free Cash Flow Margin | 17.37% | 16.00% | 17.90% | 11.71% | 5.85% | 13.38% | Upgrade
|
| EBITDA | 32,289 | 29,898 | 25,152 | 19,051 | 19,910 | 17,038 | Upgrade
|
| EBITDA Margin | 23.84% | 24.49% | 24.51% | 21.77% | 25.59% | 27.42% | Upgrade
|
| D&A For EBITDA | 8,098 | 5,827 | 3,649 | 3,168 | 1,588 | 1,135 | Upgrade
|
| EBIT | 24,191 | 24,071 | 21,502 | 15,883 | 18,322 | 15,903 | Upgrade
|
| EBIT Margin | 17.86% | 19.72% | 20.96% | 18.15% | 23.55% | 25.59% | Upgrade
|
| Effective Tax Rate | 18.29% | 20.26% | 19.06% | 21.63% | 26.42% | 23.56% | Upgrade
|
| Revenue as Reported | 140,458 | 127,442 | 105,407 | 88,780 | 79,776 | 63,854 | Upgrade
|
| Advertising Expenses | - | 7,554 | 6,008 | 3,737 | 4,516 | 3,857 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.